JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB85715

Anti-Glucose Transporter GLUT2 antibody [5D1]

4

(4 Reviews)

|

(11 Publications)

Mouse Monoclonal Glucose Transporter GLUT2 antibody. Suitable for Flow Cyt, WB, IHC-P and reacts with Human samples. Cited in 11 publications. Immunogen corresponding to Cell preparation containing SLC2A2 protein.

View Alternative Names

GLUT2, SLC2A2, GLUT-2

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Glucose Transporter GLUT2 antibody [5D1] (AB85715)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Glucose Transporter GLUT2 antibody [5D1] (AB85715)

ab85715, at 10 µg/ml, staining Glucose Transporter GLUT2 in formalin-fixed, paraffin-embedded human Liver tissue by Immunohistochemistry.

Flow Cytometry - Anti-Glucose Transporter GLUT2 antibody [5D1] (AB85715)
  • Flow Cyt

Unknown

Flow Cytometry - Anti-Glucose Transporter GLUT2 antibody [5D1] (AB85715)

Overlay histogram showing HepG2 cells stained with ab85715 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab85715, 0.5μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (ab91361, 1μg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

Western blot - Anti-Glucose Transporter GLUT2 antibody [5D1] (AB85715)
  • WB

Unknown

Western blot - Anti-Glucose Transporter GLUT2 antibody [5D1] (AB85715)

All lanes:

Western blot - Anti-Glucose Transporter GLUT2 antibody [5D1] (ab85715) at 1 µg/mL

All lanes:

Human pancreas tissue lysate - total protein (<a href='/en-us/products/unavailable/human-pancreas-tissue-lysate-total-protein-ab29816'>ab29816</a>) at 10 µg

Secondary

All lanes:

Western blot - Goat Anti-Mouse IgG H&L (HRP) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-mouse-igg-h-l-hrp-preadsorbed-ab97040'>ab97040</a>) at 1/5000 dilution

Predicted band size: 57 kDa

Observed band size: 57 kDa

true

Exposure time: 8min

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

5D1

Isotype

IgG2a

Carrier free

No

Reacts with

Human

Applications

Flow Cyt, IHC-P, WB

applications

Immunogen

Cell preparation containing SLC2A2 protein. The exact immunogen used to generate this antibody is proprietary information.

P11168

Specificity

ab85715 recognizes Glucose Transporter GLUT2 expression on hGlut2-transfected NS0 cells but not on control transfectants. Detects Glut2 on the surface of the Human intestinal cell line Caco2 in flow cytometry and on fixed cells in immunocytochemistry tests. Based on flow cytometric tests on transfected cells, this antibody has no cross-reactivity with hGlut1 or hGlut3.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "0.5 µg for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/mouse-igg2c-kappa-monoclonal-18c8bc7ad10-isotype-control-ab170191'>ab170191</a> - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.</p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1 µg/mL", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "10 µg/mL", "IHCP-species-notes": "<p></p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Storage buffer
pH: 7.4 Constituents: PBS, 5% Trehalose
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The glucose transporter GLUT2 also referred to as GLUT 2 GLUT-2 or GLUT2 transporter plays an important role in the movement of glucose across cell membranes. Mechanically it acts as a facilitative transporter allowing glucose and other monosaccharides to enter and exit cells. GLUT2 has a molecular weight of about 55 kDa. High expression of GLUT2 occurs in the liver pancreas kidney and intestines where it facilitates bidirectional glucose transport to maintain glucose balance.
Biological function summary

The role of this transporter is important for glucose sensing and regulation. It is not part of any known complex but operates efficiently as a single unit within its membrane environment. In the pancreas GLUT2 detects blood glucose levels and initiates insulin release from beta cells. In the liver it enables glucose uptake during periods of high blood glucose and facilitates glucose production when blood glucose levels drop. By performing these functions GLUT2 helps maintain glucose homeostasis in the body.

Pathways

GLUT2 is an essential component of glucose homeostasis and nutrient sensing pathways. It links to the insulin signaling pathway by facilitating insulin secretion in response to increased blood glucose. Furthermore GLUT2 associates with kinases such as AMPK which modulate cellular energy balance. The synergistic activity between GLUT2 and insulin signaling pathways highlights its central role in metabolic processes.

Altered GLUT2 function has significant implications. Mutations or deficiencies in GLUT2 can lead to conditions like Fanconi-Bickel syndrome a rare glycogen storage disorder. This transporter has been connected to diabetes as well due to its involvement in insulin secretion regulation. In both these instances GLUT2 interacts with other proteins such as glucokinase in the pancreas and liver highlighting its importance in disease pathology.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Facilitative hexose transporter that mediates the transport of glucose, fructose and galactose (PubMed : 16186102, PubMed : 23396969, PubMed : 28083649, PubMed : 8027028, PubMed : 8457197). Likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta cells; may comprise part of the glucose-sensing mechanism of the beta cell (PubMed : 8027028). May also participate with the Na(+)/glucose cotransporter in the transcellular transport of glucose in the small intestine and kidney (PubMed : 3399500). Also able to mediate the transport of dehydroascorbate (PubMed : 23396969).
See full target information SLC2A2

Publications (11)

Recent publications for all applications. Explore the full list and refine your search

Human & experimental toxicology 42:9603271231183056 PubMed37295442

2023

Renal glucose transporters play a role in removal of cadmium from kidney cells mediated by GMDTC - A novel metal chelator.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaojiang Tang,Bo Xiao,Qile Zhao,Wei Hu,Amber McKenery,Zhiyong Zhong

Cytotechnology 72:499-511 PubMed32409919

2020

Characterization of Huh7 cells after the induction of insulin resistance and post-treatment with metformin.

Applications

Unspecified application

Species

Unspecified reactive species

José Manuel Villalva-Pérez,Marco Antonio Ramírez-Vargas,Jesús Isimar Serafín-Fabían,Mónica Ramírez,Ma Elena Moreno-Godínez,Mónica Espinoza-Rojo,Eugenia Flores-Alfaro

Cells 9: PubMed32093016

2020

The VDAC1-based R-Tf-D-LP4 Peptide as a Potential Treatment for Diabetes Mellitus.

Applications

Unspecified application

Species

Unspecified reactive species

Srinivas Pittala,Idan Levy,Soumasree De,Swaroop Kumar Pandey,Nataly Melnikov,Tehila Hyman,Varda Shoshan-Barmatz

American journal of physiology. Regulatory, integrative and comparative physiology 318:R38-R48 PubMed31596114

2019

Evidence that hindbrain astrocytes in the rat detect low glucose with a glucose transporter 2-phospholipase C-calcium release mechanism.

Applications

Unspecified application

Species

Unspecified reactive species

Richard C Rogers,Susan J Burke,J Jason Collier,Sue Ritter,Gerlinda E Hermann

International braz j urol : official journal of the Brazilian Society of Urology 45:169-178 PubMed30521176

2018

Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications.

Applications

Unspecified application

Species

Unspecified reactive species

Minoru Kobayashi,Toshitaka Uematsu,Yuumi Tokura,Kohei Takei,Kazumasa Sakamoto,Takahiro Narimatsu,Akinori Nukui,Takao Kamai

Oncology letters 12:3337-3343 PubMed27900001

2016

Expression of glucose transporter-1 is correlated with hypoxia-inducible factor 1α and malignant potential in pancreatic neuroendocrine tumors.

Applications

IHC-P

Species

Human

Minoru Fujino,Shinichi Aishima,Koji Shindo,Yasunori Oda,Katsuya Morimatsu,Kosuke Tsutsumi,Takao Otsuka,Masao Tanaka,Yoshinao Oda

American journal of clinical pathology 142:391-7 PubMed25125631

2014

Correlation between biological marker expression and fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma.

Applications

Unspecified application

Species

Human

Yohei Mano,Shinichi Aishima,Yuichiro Kubo,Yuki Tanaka,Takashi Motomura,Takeo Toshima,Ken Shirabe,Shingo Baba,Yoshihiko Maehara,Yoshinao Oda

Obesity (Silver Spring, Md.) 22:2164-71 PubMed24990218

2014

Upregulation of intestinal glucose transporters after Roux-en-Y gastric bypass to prevent carbohydrate malabsorption.

Applications

Unspecified application

Species

Unspecified reactive species

Nam Q Nguyen,Tamara L Debreceni,Jenna E Bambrick,Bridgette Chia,Adam M Deane,Gary Wittert,Chris K Rayner,Michael Horowitz,Richard L Young

Diabetes 63:3295-309 PubMed24760138

2014

Liver-restricted Repin1 deficiency improves whole-body insulin sensitivity, alters lipid metabolism, and causes secondary changes in adipose tissue in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Matthias Kern,Joanna Kosacka,Nico Hesselbarth,Julia Brückner,John T Heiker,Gesine Flehmig,Ingrid Klöting,Peter Kovacs,Madlen Matz-Soja,Rolf Gebhardt,Knut Krohn,Susanne Sales,Kerstin Abshagen,Andrej Shevchenko,Michael Stumvoll,Matthias Blüher,Nora Klöting

Critical care medicine 42:57-65 PubMed23963126

2013

The effects of critical illness on intestinal glucose sensing, transporters, and absorption.

Applications

Unspecified application

Species

Unspecified reactive species

Adam M Deane,Chris K Rayner,Alex Keeshan,Nada Cvijanovic,Zelia Marino,Nam Q Nguyen,Bridgette Chia,Matthew J Summers,Jennifer A Sim,Theresia van Beek,Marianne J Chapman,Michael Horowitz,Richard L Young
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com